RESEARCH ARTICLE
Role of Serum Cystatin C as a Diagnostic Tool for Renal Function in Cirrhotic Patients
Fathia Elsayed Asal1, Mohamed Yousef1, Hend Atteya Abdelkhalek Abdraboh1, Sherief Abd-Elsalam1, *, Ahmed Abdelaziz Abdelaziz Shama2, Mohamed Elbahnasawy3, Mohammed H Elnaggar4, Hesham Ahmed Alsrogy5, Heba Elashry1
Article Information
Identifiers and Pagination:
Year: 2022Volume: 12
E-location ID: e187531832203210
Publisher ID: e187531832203210
DOI: 10.2174/18753183-v12-e2203210
Article History:
Received Date: 7/10/2021Revision Received Date: 13/12/2021
Acceptance Date: 20/1/2022
Electronic publication date: 08/04/2022
Collection year: 2022
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background:
Assessment of cystatin C levels could be valuable in the early detection of renal dysfunction because they increase faster than the creatinine levels as the GFR decreases. The aim of this work was to evaluate serum cystatin C as a diagnostic tool for renal dysfunction in cirrhotic patients with and without hepatorenal syndrome (HRS).
Methods:
This case-control study was conducted on 60 patients from the Tropical Medicine Department of Tanta University Hospitals and 10 people served as healthy control volunteers. Serum cystatin C was measured in the three groups.
Results:
A significant difference was observed among the three groups as cystatin C was higher in patients with HRS compared to the cirrhotic group and healthy controls.
Conclusion:
Serum cystatin C is a good predictor for hepatorenal syndrome with a good correlation with serum creatinine, blood urea, GFR, and creatinine clearance.
